The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.
 
Daniel V.T. Catenacci
Honoraria - Amgen; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Genmab; Gritstone Bio; Guardant Health; Lilly; Merck; NantWorks; OncoPlex Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Genentech/Roche; OncoPlex Diagnostics
Speakers' Bureau - Foundation Medicine; Guardant Health
Research Funding - Genentech; OncoPlex Diagnostics
 
Peter C. Enzinger
Consulting or Advisory Role - Astellas Pharma; Five Prime Therapeutics; Merck; Taiho Pharmaceutical
 
Anteneh A. Tesfaye
No Relationships to Disclose
 
Mohamedtaki Abdulaziz Tejani
Research Funding - Bayer (Inst)
 
Janine Powers
Employment - Five Prime Therapeutics; Five Prime Therapeutics
Stock and Other Ownership Interests - Pfizer
Patents, Royalties, Other Intellectual Property - multiple patents for FGFRs in hair growth
 
Charlie Zhang
Employment - Amgen (I); Biomarin; Biomarin (I); Five Prime Therapeutics
Stock and Other Ownership Interests - Biomarin (I); Bluebird Bio; Exelixis; Five Prime Therapeutics; Gilead Sciences (I)
Travel, Accommodations, Expenses - Biomarin; Five Prime Therapeutics; Five Prime Therapeutics
 
Neyssa Marina
Employment - Five Prime Therapeutics; Genentech/Roche (I)
Stock and Other Ownership Interests - Five Prime Therapeutics; Genentech/Roche (I)
Travel, Accommodations, Expenses - Five Prime Therapeutics
Other Relationship - Bristol-Myers Squibb; GlaxoSmithKline; Macrogenics; Novartis
 
Clarence Eng
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
 
Eric Cheung
No Relationships to Disclose
 
Aaron James Scott
No Relationships to Disclose
 
Peter D. Eisenberg
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); AVEO (Inst); Biomarin (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Intercept Pharmaceuticals (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Millennium (Inst); PharmaMar (Inst); Plexxikon (Inst); Puma Biotechnology (Inst); Spectrum Pharmaceuticals (Inst); TG Therapeutics (Inst); Toray Industries (Inst)